SMARCC2 and cancer: Mutations or loss of a single critical mSWI/SNF subunit, such as SMARCB1 in malignant rhabdoid tumors and epithelioid sarcoma, ARID1A in a wide variety of cancers including ovarian clear cell carcinoma, endometrioid carcinoma, neuroblastoma, and bladder cancer, BRG1 in medulloblastoma, breast and lung cancers, SMARCC1 in small cell lung cancer, and SMARCC2 in pancreatic cancer, uniquely causes the proteolysis of other subunits2,3,12–15.